**Date:** 22.08.2022

Curriculum Vitae and List of Publications

Dr. Nimer Assy

**1. Personal Data**

|  |  |
| --- | --- |
| Name: Nimer Assy | Identity or Passport Number: 57009193 |
| Place of Birth: Fassouta, Upper Galilee | Date of Birth: 10.09.1961 |
| Date of Immigration: N/A | Family Status: Married +5 |
| Citizenship status: Israeli | Permanent Address: Fassouta, Western Galilee, 251700 |
| Phone Number: 04-9107746 (w); 050-7887915 (m) | E-mail: nimera@gmc.gov.il |

**2. Proposed academic rank:**

**3. Education, Academic Degrees, Residencies, and Fellowships**

|  |  |  |  |
| --- | --- | --- | --- |
| **From-To** | **Institution** | **Area of Specialty** | **Degree or Certification, Year** |
| **MD\DMD Studies** | University of Louvain (UCL), Belgium |  | 1987 |
| **Primary Residency Subspeciality Residency:** | Rambam Medical Center | Internal Medicine | 1994 |
| **Fellowship:** | University of Manitoba, Canada  University of Western Ontario, Canada | Hepatology  Liver transplantation | ?  ? |
| **Other Academic Degrees:** |  |  |  |

**MD Thesis Title**: Diabetic Nephropathy

**Supervisor**: Professor Rahier, University of Louvain (UCL), Belgium

**4. Academic Appointments**

|  |  |  |
| --- | --- | --- |
| **From-To** | **Academic Rank** | **University** |
| 2011-present | Associate Professor | Azrieli Medical School, BIU |
| 2007-2011 | Senior Lecturer | The Technion - Israel Institute of Technology |

**5. Teaching contributions Faculties of Medicine:**

|  |  |  |
| --- | --- | --- |
| **From-To** | **Teaching Role or Position** | **Institution** |
| 2012-present | Interviewer for student admission | Azrieli Medical School, BIU |
| 2011-2021 | Hepatology lectures | Azrieli Medical School, BIU |
| 2011-2015 | Head of the Student Health Committee | Azrieli Medical School, BIU |
| 2011-2015 | Student entrance examiner | Azrieli Medical School, BIU |
| 2011-2015 | M.Sc. examiner | Azrieli Medical School, BIU |
| 2011-2015 | Ph.D examiner | Azrieli Medical School, BIU |
| 2011-2014 | Coordinator for Bioenergetic course | Azrieli Medical School, BIU |

**6. Professional Staff Appointments (at Medical Institutions):**

|  |  |  |
| --- | --- | --- |
| **From-To** | **Position** | **Institution** |
| 2015-present | Department Head | Galil Medical Center, Nahariya, Internal Medicine A |
| ? | Clerkship, 24 weeks for 4th year students | Galil Medical Center, Nahariya, Internal Medicine A |
| ? | Clerkship, 4 weeks for 6th year students | Galil Medical Center, Nahariya, Internal Medicine A |
| 2007-2014 | Head of Liver Services | Ziv Medical Center |

**7.** **Supervision of Graduate , Post-Graduate Students and Medical Students**

|  |  |  |  |
| --- | --- | --- | --- |
| **Name of Student/ Trainee and Supervision of Research Project for Specialty Residents Trainees** | **Degree, Years Supervised** | **Thesis or Project Title** | **Publication(s) with student as Author (refer to number in publication list)** |
| Nasrin Ganim | M.Sc. 2019 |  |  |
| Eti Azulai | PhD, 2018-2019 | Degree not completed due to family issues |  |
| Natali Silberstein | For final MD project, 2013 |  |  |
| Marva Harpak | For final MD project, 2013 |  |  |
| Joenna Araf | For final MD project, 2014 |  |  |
| Maayan Parkin | For final MD project, 2015 |  |  |
| Nidaa Nasser | For final MD project, 2016 |  |  |
| Joseph Nasser | For final MD project, 2017 |  |  |
| Hiba Nasser | For final MD project, 2018 |  |  |
| Dr. Walid Kassis | Basic science, clinical research 2020 |  |  |
| Dr. Amad Abu Shkara | Basic science, clinical research 2020 |  |  |
| Dr. Ahmad Yasin | Basic science, clinical research 2019 |  |  |
| Dr. Simon Abu Shkara | Basic science, clinical research 2019 |  |  |
| Dr. Azuar Nagar | Basic science, clinical research 2018 |  |  |
| Dr. Alaa Amasa | Basic science, clinical research 2017 |  |  |
| Dr. Coliada Alexander | Basic science, clinical research 2015 |  |  |
| Dr. Jubran Waal | Basic science, clinical research 2014 |  |  |
| Dr. Alla Ibn Salach | Basic science, clinical research 2014 |  |  |
| Dr. Asla Husam | Basic science, clinical research 2014 |  |  |

**8. Competitive Research Funding Sources**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Start and Completion Dates** | **Funding Agency** | **Competitive or sponsored** | **Status (e.g, PI, Co-PI)** | **Title** | **Total Funds for Grant** |
| 2018-2019 | Israel Cancer Society | Competitive | PI  In cooperat-ion with Dr. Idan Cohen | Characterization of recurrent mutation in H2B histone variants as potential novel oncohistone mutations controlling human jumping genes. | NIS 75,000 |

**9. CONFERENCES**

1. Participation in organizing conferences
2. Plenary or invited talks
3. Contributed Talks, Posters and abstracts (Conference title, location, date, name of speaker. Please mention Talk\Poster\Abstract)
4. Refereed papers in conference proceedings (Include all co-authors in the order they appear on the paper, title of paper, title of publication, publisher, first and last pages, and year; do not list abstracts)

a. National Conferences

|  |  |  |
| --- | --- | --- |
| **Name of Conference** | **Place and Date** | **Title of Lecture/Poster** |
| **Participation in organizing conferences** | | |
| Conferences of The International Association for the Study of the Liver (IASL) | 2007-2011 | Member of organizing committee |
| Meeting for World Hepatitis Awareness Day | Nazareth, Israel  28th July, 2009 | Member of organizing committee |
| First International Liver Meeting | Tiberius, Israel  May 2010 | Member of organizing committee |
| EASL Clinical School | Jerusalem, Israel  May, 2011 | Chair of session on resection, ablation, and liver transplantation of hepatocellular carcinoma |
| Kenes Biorefuah | Tel Hai, Israel  October 2011 | Session chair and member of organizing committee |
| **Plenary Presentations** | | |
|  |  |  |
| **Invited non-Plenary** | | |
| DOT 2009 | Tel Aviv, Israel  2009 | Fatty liver disease |
| DOT 2010 | Tel Aviv, Israel  2010 | Soft drink consumption (fructose) and fatty liver |
| IASL | Tel Aviv, Israel  2010 | Pharmacological therapy in NAFLD-atherosclerosis |
| Northern Committee for Diabetes, Obesity, and Hypertension | Haifa, Israel  September, 2011 | Fatty liver as a cardiovascular risk factor |
| Liver Meeting – Northern Committee | 2007-2011 | HBV, fatty liver, HCV |
| **Contributed Talks, Posters and Abstracts at National Conferences** | | |
| N/A |  |  |
| **Refereed papers in conference proceedings** | | |
| N/A |  |  |

b. International Conferences in Israel

|  |  |  |
| --- | --- | --- |
| **Name of Conference** | **Place and Date** | **Title of Lecture/Poster** |
| **Participation in organizing conferences** | | |
|  |  |  |
| **Plenary Presentations** | | |
|  |  |  |
| **Invited non-Plenary** | | |
|  |  |  |
| **Contributed Talks, Posters and Abstracts** | | |
|  |  |  |
| **Refereed papers in conference proceedings** | | |
|  |  |  |

c. International Conferences Abroad

|  |  |  |
| --- | --- | --- |
| **Name of Conference** | **Place and Date** | **Title of Lecture/Poster** |
| **Participation in organizing conferences** | | |
| First world congress of viruses and infections (WCV1-2010) | Busan, Korea  July 2010 | Hepatitis C and the Metabolic Syndrome: Chairman of session (3 hours) on hepatitis B |
| **Plenary or invited talks** | | |
|  |  |  |
| **Invited non-Plenary** | | |
| European Association for the Study of the Liver (EASL) – Satellite symposium “Prospects for Improved Liver Disease Management in Chronic Hepatitis B; personal approach of patients with HBV” | Berlin, Germany  2004 | A day in the life of Dr Assy N. |
| EHRLICH II - 2nd World Conference on Magic Bullets | Nuremberg, Germany  October 2008 | The changes in renal function after a single dose of intravenous Furosemide in patients with compensated liver cirrhosis |
| EASL | Vienna, Austria,  April 2010 | Vitamin D supplements improve SVR in chronic hepatitis C in naïve patients treated with Peg interferon alpha and ribavirin |
| EPS Global 1ST International Conference of microbes, (WCM1-2011) | Beijing, China  July 2011 | Vitamin D and chronic liver disease |
| Belt & Road International Conference on Hepatobiliary Carcinoma and Infectious Diseases (BRICHID) | University of Beijing, China  July 2019 | IGF-1 as a liver reserve assessment tool in hepatocellular carcinoma |
|  |  |  |
| **Contributed Talks, Posters and Abstracts** | | |
| N/A |  |  |
| **Refereed papers in conference proceedings** | | |
| 1. **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated Insulin like growth factor 1 (IGF-1) and binding protein -3 in liver cirrhosis. J Hepatol 1997; 27: 796-802, EASL, AASLD, IASL 2. **Assy N**, Adams PC. Predictive value of family history in diagnosis of hereditary hemochromatosis. Dig Dis Sci. 1997; 42:1312-5. 3. **Assy N**, Gong YW, Zhang M, Pashniak D and Minuk GY. The use of proliferating cell nuclear antigen as a marker of liver regeneration following partial hepatectomy in rats. J Lab Clin Med 1998; 131:251-256. (AASLD) 4. **Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. Gastrointestinal Endoscopy 1999; 49:690-694 (AASLD) 5. **Assy N**, Kaita KDE, Mymin D, Levi C and Minuk GY. Fatty infiltration of the liver in hyperlipidemic patients. Dig Dis SCI 2000; 45:1929-1934 (AASLD) 6. **Assy N**, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid. Transplantation. 2007; 83:1571-1576.(AASLD) 7. Abid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N**. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009; 51:918-24 (EASL) 8. **Assy N**, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010; 254:393-400 (EASL, AASLD) 9. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, **Assy N**. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011 17:5184-90. 10. Kamaysi Iyad, Nseir William, Alexandrov Olga, Isakson Alex, Mysh Vladimir, Dabbah Kamal, and **Assy Nimer**. Sub clinical hepatic encephalopathy in cirrhotic Patients is not aggravated by sedation with propofol compared to midazolam. J Hepatol. 2011; 54:72-7. | | |

d.

|  |  |  |
| --- | --- | --- |
| **Invited Professorships Institution** | **Grand Rounds Date** | **Title:** |
| N/A |  |  |
|  |  |  |

**10.**  **Miscellaneous**

|  |  |
| --- | --- |
| **Date** | **Membership** |
|  | Member of the Israel Association for the Study of the Liver (IASL) |
|  | Member of the European Association for the Study of the Liver (EASL) |
|  | Member of the American Association for the Study of Liver Disease (AASLD) |
| **Date** | **Patent (Title, Status, Date)** |
| July 2009 | Grosovski M, Maoz M, **Assy N**. Therapy of NAFLD utilizing Inula Viscosa Extract. State of Israel. **Application** **Number 199847** |
|  |  |
| **Date** | **Honors and Awards** |
| ? | An inspiring lecturer award from the National Student Association |
| 2020 | “Matzpen” program award (Northern stars) given to two physicians, Azrieli Medical School, Tzfat |
| 2012-2020 | Consistently received the Outstanding Lecturer Award, Azrieli Medical School, Tzfat |
| 2017 | “Marquis Who’s Who”, Best Author in Medicine |

**11.** **Public Scientific Activities Outside the University**

|  |  |
| --- | --- |
| **From-To** | **Type of Activity or Appointment** |
| 2014-present | Member of the National Council for Liver Diseases and Nutrition |
| 2014-present | Member, Mapping of the Physicians Reserve Committee, Galil Medical Center |
| 2014-present | Examiner in Phase I and Phase II exams |
| 2012-2015 | “Health basket” consultant in the liver field |
| 2011-2015 | Member of the Liver Committee of the Ministry of Health |
| 2011-2015 | Head of the Maccabi Health Clinic in the village of Fassouta |
| 2011-2015 | Advisor on liver health for Clalit and Maccabi Health Services |
| 2011-2015 | Member of the Mortality Committee of the Ministry of Health |
| 2011-2015 | Member of the Fellowship Committee for the Advancement of Physicians, Galil Medical Center |
| 2011-2015 | Chairman of the Recognition Committee for Scientific Council Internships |

**12. List of Publications**

1. **Hypothesis-driven clinical or basic research**

Until last promotion:

1. **Assy N**, and Adams PC. Predictive value of family history in the diagnosis of hereditary Hemochromatosis. Dig Dis Sci 1997; 42:1312-1315.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

2. **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated Insulin like growth factor 1 (IGF-1) and binding protein -3 in liver cirrhosis. J Hepatol 1997; 27: 796-802

IF: 9.33, Rank: 4/71(Gastro&hepatol). Contribution: A,B,C,D

3. Minuk GY, **Assy N**, Ding LX, Gauthier T, and Pashniak D. Effect of quinolone antibiotics on hepatic growth and protein synthesis following partial hepatectomy in rats. J Gastroenterol Hepatol 1997; 12: 54-57. Comment in: J Gastroenterol Hepatol 1997; 12: 44-6

IF:2.4, Rank: 33/71(Gastro&hepatol). Contribution: B,D

4. Baruch Y, **Assy N**, Kramsky R, and Enat R. Safety of conversion from cyclosporine sand immune to cyclosporine neoral in stable liver transplant patients. Transplant Proc 1998; 30:1852-1853.

IF:0.99, SJR 0,124 (transplant). Contribution: A,B,C,D

5. **Assy N**, Hochberg Z, Enat R, and Baruch Y. Prognostic value of GH-stimulated insulin- Like growth factor -1 (IGF-1) and its binding (IGBP-3) generation in patients with compensated and decompensated liver cirrhosis. Dig Dis Sci 1998; 43:1317-1321.

IF: 2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

6 Baruch Y, **Assy N**, Amit T, and Hochberg Z. Spontaneous pharmacokinetics of growth hormone in liver cirrhotic patients. J Hepatol 1998; 28:414-419

IF:9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D

7. Kaita KDE, **Assy N**, Gauthier T, and Minuk GY. The beneficial effects of Ciprofloxacin on survival and hepatic regenerative activity in an animal model of Fulminant hepatic failure. Hepatology 1998; 27:533-536

IF: 10.88, Rank: 2/71(Gastro&hepatol). Contribution: A,C,D

8. **Assy N**, Gong YW, Zhang M, Pashniak D and Minuk GY. The use of proliferating cell nuclear antigen as a marker of liver regeneration following partial hepatectomy in rats. J Lab Clin Med 1998; 131:251-256.

IF: 2.19, Rank: 5/18 (medical laboratory technology category). Contribution: A,B,C,D

9. Baruch Y, **Assy N**, Reisner S, Blendis LM, Berry E, Enat R, and Bomzon A. A pilot study on the hemodynamic effect of short term ursodeoxycholic acid therapy in patients with stable liver cirrhosis. Am J Gastroenterology. 1999; 94:3000-3004.

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

10**. Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. Gastrointestinal Endoscopy 1999; 49:690-694.

IF: 5.6, Rank: 7/71 (Gastro&hepatol). Contribution: A,B,C,D

11. **Assy N**, Paizi M, Gaitini D, Baruch Y, and Spira G. Clinical implication of serum VEGF levels in cirrhotic patients with or without portal hypertension. World J Gastroenterology1999; 5: 296-300.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

12. **Assy N**, Gong YW, Zhang M and Minuk GY. Appearance of an inhibitory cell nuclear antigen In rat and human serum during variable degrees of hepatic regenerative activity. World J Gastroenterol (WJG) 1999; 5:103-107.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

13. **Assy N**, Spira G, Paizi M, Shankar L, Kraizer Y, Cohen T, Neufeld G, Dabbah B, and Baruch Y. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol 1999; 30:911-915

IF: 9.33, Rank: 4/71(Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

14. **Assy N**, Kaita KDE, Mymin D, Levi C and Minuk GY. Fatty infiltration of the liver in Hyperlipidemic patients. Dig Dis SCI 2000; 45:1929-1934

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

15. **Assy N**, and Minuk GY. Serum aspartate aminotransferase (AST) values as a useful predictor of histologic features of chronic HCV infection in adults. Am J Gastroenterology 2000; 95:1545-1551.

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

16. M Zhang, Gong W, **Assy N,** and GY Minuk. Regulation of alpha fetoprotein and albumin gene expression by gamma-aminobutric acid receptor agonists in a human hepatocellular carcinoma cell line. J Hepatol 2000; 32:85-91

IF: 9.33, Rank: 4/71(Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

17. Edoute Y, Hussein O, Malberger E, Yerushalmi R, Tibon-Fisher O, **Assy N.** Diagnostic accuracy of direct fine-needle aspiration of levier lesions: a prospective study of 107 patients in peripheral community center with limited technological capability. Arch gastroenterohepatology 2001; 20:19-24. (Editorial 20:14-18).

IF:1.67, Rank: 98/114, SJR 0.025 (Gastro&hepatol). Contribution: A,B,C,D

18. Kraizer Y, Mawasi N, Seagal J, Paizi M, **Assy N**, Spira G. Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem Biophys Res Com 2001; 87:209-215

IF:2.59, Rank: 25/121, SJR 0,398 (Biophysics). KY. Research Student. Contribution: A,B,C,D

19. Hussein O, Szvalb S, Van den Akker-Berman LM, and **Assy N**. Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation. Dig Dis Sci. 2002; 47:1926-31.

IF:2.06, Rank: 40/71(Gastro&hepatol). VL, research student, Contribution: A,B,C,D

20. **Assy N**, Bekirov I, Mejiritsky Y, Solomon L, Szvalb S, and Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic Fatty liver disease. World J gastroenterology 2005; 11(37):5834-9.

IF: 2.24, Rank: 35/71(Gastro&hepatol). BI, Research student. Contribution: A,B,C,D

21. **Assy N**, Kayal M, Mejirisky Y, Gorenberg I, Hussein O, and Sorina Schlesinger. The Changes in Functional Renal Mass after a Single Dose of Intravenous Furosemide in Patients with Compensated Liver cirrhosis. BMC Gastroenterol. 2006; 6:39.

IF:2.46, Rank: 32/71 (Gastro&Hepatol). A.M. Research Student. Contribution: A,B,C,D

22. [**Assy N**, Grozovski M, Bersudsky I. Szvalb S, Hussein O.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16865780&query_hl=1&itool=pubmed_docsum) Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol. 2006; 12:4369-76.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

23. Hussein O, Schlesinger S, Szvalb S, and **Assy N.** Orlistat reverse fatty infiltration and improve hepatic fibrosis in obese patients with nonalcoholic steatohepatitis NASH). Dig Dis Sci 2007; 52:2512-9.

IF:2.06, Rank: 40/71(Gastro&hepatol ). Contribution: A,B,C,D

24.[Hussein O, Gefen Y, Zidan JM, Karochero EY, Luder AS, **Assy N**, Sror ES, Aviram MY.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17070510&query_hl=1&itool=pubmed_docsum) LDL oxidation is associated with increased blood hemoglobin A1c levels in diabetic patients. Clin Chim Acta. 2007; 377:114-8.

IF: 2.53, SJR 0.23 ([Biomedical Sciences](http://www.google.com/url?q=http://biomedicalsciencesblog.blogspot.com/2010/06/2009-journal-impact-factors.html&sa=U&ei=PYhDTtK3BoTJswaf88mjAg&ved=0CBMQFjAB&sig2=kpWOBmK-hf2LSR2k4Af1Ng&usg=AFQjCNHnwQwS57W-KPEULIOzcN0opfj5JQ)). Contribution: D

25.[**Assy N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Assy%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Pettigrew N](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pettigrew%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lee SS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20SS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Chaudhary RK](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chaudhary%20RK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Johnston J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Johnston%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Minuk GY](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Minuk%20GY%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Are Chronic Hepatitis C Viral Infections More Benign in Patients with Hemophilia? [Am J Gastroenterol.](javascript:AL_get(this,%20'jour',%20'Am%20J%20Gastroenterol.');) 2007;102:1672-6

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

26. [A**ssy N**, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17589339&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid. Transplantation. 2007; 83:1571-1576.

IF:3.67, Rank: 11/40 (Surg). Contribution: A,B,C,D

27**.** [A**ssy N**, Hussein O, Khalil A, Luder A, Szvalb S, Paizi M, Spira G.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17372820&ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci. 2007; 52:1187-93

IF:2.06, Rank: 40/71(Gastro&Hepatol). A.K. Research Student. Contribution: A,B,C,D

28. [Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, **Assy N**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17230603&query_hl=1&itool=pubmed_docsum) Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J Gastroenterol. 2007; 13:361-368

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

29. **Assy N**, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, Grosovski M. [Soft drink consumption linked with fatty liver in the absence of traditional risk factors.](http://www.ncbi.nlm.nih.gov/pubmed/18925303) Can J Gastroenterol. 2008; 22:811-6.

IF:1.55, Rank: 49/71 (Gastro&hepatol). Contribution: A,B,C,D

30. **Assy N**, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y. [Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepato cellular dysfunction.](http://www.ncbi.nlm.nih.gov/pubmed/18456366) J Hepatol. 2008; 49:34-42

IF:9.33, Rank: 4/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

31. **Assy N**, Beniashvili Z, Djibre A, Nasser G, Grosovski M, Nseir W. [Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers.](http://www.ncbi.nlm.nih.gov/pubmed/19554656) World J Gastroenterol. 2009 ;15:3025-31

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

32. Aid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N**. [Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome.](http://www.ncbi.nlm.nih.gov/pubmed/19765850) J Hepatol. 2009; 51:918-24

IF:9.33, Rank: 4/71 (Gastro&hepatol). A.A. Research Student. Contribution: A,B,C,D

33. **Assy N**, Djibre A, Farah R, Grosovski M, Marmor A. [Presence of coronary plaques in patients with nonalcoholic fatty liver disease.](http://www.ncbi.nlm.nih.gov/pubmed/20093511) Radiology. 2010 ;254:393-400

IF:6.06, Rank: 2/40 (Radiology). D.A. Research Student. Contribution: A,B,C,D

34. Nseir W, Khateeb J, Tatour I, Haiek I, and **Assy N**. Long Term Statin Therapy May Reduce the Severity of Chronic Gastritis. Helicobacter 2010; 15:510-5.

IF:3.1, Rank: 10/25 (Gastro). Research Student. Contribution: A,B,C,D

35. Kamaysi I, Nseir W, Alexandrov O, Isakson A, Mysh V, Dabbah K, and **Assy N**. Subclinical hepatic encephalopathy in cirrhotic Patients is not aggravated by sedation with propofol compared to midazolam. J Hepatol. 2011; 54:72-7.

IF:9.33, Rank: 4/71 (Gastro&hepatol). A.O. Research Student. Contribution: A,B,C,D

36. Nseir W, Hussein T, Khateeb J, Grosovski M, and **Assy N**. Fatty Liver Disease is Associated with Recurrent Bacterial Infections Independently of Metabolic Syndrome. Dig Dis Sci. 2011; 56:3328-3334

IF:2.06, Rank: 40/71(Gastro&hepatol ). Contribution: A,B,C,D

Since last promotion:

1. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, **Assy N**. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. **2011**; 17:5184-90.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

2. Elias W, **Assy N**, Elias I, Toledo T, Yassin M, Bowirrat A. The detrimental danger of Water-Pipe (Hookah) transcends the hazardous consequences of general health to the driving behavior. J Transl Med. 2012;10:126.

IF 4.098 Rank: 41/136 (Medicine, Research & Experimental). Contribution: A,B,C,D

3. **Assy N**, Basher W, Chetver L, Shnaider J, Zidan J. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. J Clin Gastroenterol. **2012**; 46:e27-30.

IF 2.724 Rank: 54/84 (Gastroenterology & Hepatology). Contribution: C,D

4. Nseir W, Mograbi J, Di Castro N, Abu-Elheja O, Abu-Rahmeh Z, Khamaysi I, Samara M, **Assy N**. On the association between soft drink consumption and Helicobacter pylori infection. Dig Dis Sci. **2012** ;57:981-6.

IF 2.937 Rank: 48/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

5. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, **Assy N**. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection. **2012**; 40(1):41-8.

IF 2.927 Rank: 39/89 (Infectious Diseases). Contribution: A,B,C,D

6. **Nimer A**, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol**. 2012**; 18:800-5.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

7. Josef P, Ali I, Ariel P, Alon M, **Nimer A**. Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD). Int J Environ Res Public Health. **2013**; 10:3409-23.

IF 2.14, Rank 73/180 ('Public, Environmental & Occupational Health'). Contribution: A,B,C,D

8. Zelber-Sagi S, Webb M, **Assy N**, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol. **2013**; 19:57-64.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

9. Dabbah S, Komarov H, Marmor A, **Assy N**. Epicardial fat, rather than pericardial fat, is independently associated with diastolic filling in subjects without apparent heart disease. Nutr Metab Cardiovasc Dis. **2014** ;24:877-82

IF 3.340 Rank: 33/86 (Nutrition & Dietetics). Contribution: A,B,C,D

10. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. **2014**; 12:2085-91.e1.

IF 7.958 Rank: 8/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

11. Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y, **Nimer A**, Hemed N, Zolotarovya L, Lichtenstein Y, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y. Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. J Clin Immunol. **2015**; 35:399-407.

IF 4.128 Rank: 54/158 (Immunology). Contribution: B, D

12. Farah R, Gilbey P, Grozovski M, Asli H, Khamisy-Farah R, **Assy N**. [Antioxidant Enzyme Activity and Cognition in Obese Individuals with or without Metabolic Risk Factors.](https://www.ncbi.nlm.nih.gov/pubmed/27657994) Exp Clin Endocrinol Diabetes. **2016**; 124:568-571

IF 1.927 Rank: 115/145 (Endocrinology & Metabolism). Contribution: A,B,C,D

13. Flisiak R, Kawazoe S, Znoyko O, **Assy N**, Gadano A, Kao JH, Lee KS, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. [Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.](https://www.ncbi.nlm.nih.gov/pubmed/27327078) J Interferon Cytokine Res. **2016** ;36:635-643.

IF 1.774 Rank: 134/158 (Immunology). Contribution: B,D

14. Frank Wolf M, Peleg D, Kariv Silberstein N, **Assy N**, Djibre A, Ben-Shachar I. Correlation between changes in liver stiffness and preeclampsia as shown by transient elastography. Hypertens Pregnancy. **2016**; 35:536-541.

IF 1.736 Rank: 53/83 (Obstetrics & Gynecology). Contribution: A,B,C,D

15. Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, **Nimer A**, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O. [HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.](https://www.ncbi.nlm.nih.gov/pubmed/28067632) Antivir Ther. **2017**; 22:431-441.

IF 2.305 Rank: 23/36 (Virology). Contribution: B,D

16. Zelber-Sagi S, Bord S, Dror-Lavi G, Smith ML, Towne SD Jr, Buch A, Webb M, Yeshua H, **Nimer A**, Shibolet O. Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients. World J Gastroenterol. **2017**; 23:1881-1890.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

17. Eliyahu S, Sharabi O, Elmedvi S, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, **Nimer A**, Braun M, Weiss YY, Polak P, Yaari G, Gal-Tanamy M. Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance. Front Immunol. **2018**; 9:3004.

IF 4.716 Rank: 43/158 (Immunology). Contribution: B,D

18. Gozlan Y, Bucris E, Shirazi R, Rakovsky A, Ben-Ari Z, Davidov Y, Veizman E, Saadi T, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Katchman H, Menachem Y, Safadi R, Galun E, Zuckerman E, **Nimer A**, Hazzan R, Maor Y, Saif AM, Etzion O, Lurie Y, Mendelson E, Mor O. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data. Antivir Ther. **2019**; 24:221-228.

IF 2.305 Rank: 23/36 (Virology). Contribution: B,D

19. Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019; 15:e1008181.

IF 5.224 Rank: 23/173 (Genetics & Heredity). Contribution: B,D

20. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 ;381:1215-1226.

IF 70.670 Rank: 1/160 (Medicine, General & Internal). Contribution: B,D

21. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50:333-344

IF 2.961 Rank: 20/80 (Urology & Nephrology). Contribution: B,D

22. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50:345-356

IF 2.961 Rank: 20/80 (Urology & Nephrology). Contribution: B,D

23. Kadah A, Khoury T, Mahamid M, **Assy N**, Sbeit W. Predicting common bile duct stones by non-invasive parameters. Hepatobiliary Pancreat Dis Int. 2020. pii: S1499-3872(19)30221-8.

IF 1.576 Rank: 78/84 (Gastroenterology & Hepatology). Contribution: C, D

24. Lim JJ, Nilsson AC, Silverman M, **Assy N**, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A virus infection. Antimicrob Agents Chemother. 2020; 64:e00352-20.

25. Basheer M, Saad E and **Assy N.** Methylprednisolone Decrease In - Hospital Mortality in Patients with COVID-19 Pneumonia. Japanese J Gastro Hepato. 2021; V5(12): 1-1

26. Basheer M, Saad E and **Assy N**. Low (HDL) Lipoprotein Levels is Strongly Correlated with The Severity of Covid -19 Pneumonia. Japanese J Gastro Hepato. 2021; V5(12): 1-2

27. **Assy N**, Saad E, Basheer M, Assy Najib and Sbeit W. New Predictor of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. Clin Gastroenterol Int. 2021; 3(1): 1017.

1. **Clinical Descriptive Research** (e.g. retrospective studies)

Until last promotion.

1. **Assy N**, Blumenfeld Z, Berkovitz D, Nave Y, Kramsky R, Rosenthal E, Enat R, and Baruch Y. Long term follow up of liver transplant patients in a non-liver transplantation center. Transplant Proceed 1997; 29:2664-2666.

IF: 0.99, Rank: x/y (Transplant). Contribution: A,B,C,D

2. Edoute Y, Malberger E, Tibon-Fisher O, **Assy N**. Non- imaging-guided fine needle aspiration of liver lesions: A retrospective study of 279 patients. World J Gastroenterology (WJG) 1999; 5:98-103. Invited Commentary WJG 1999; 5:98-102.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

3. Hoffman R, **Assy N**, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: A report of 6 patients. Liver Transpl Surg1999; 5:96-100.

IF:3.05, Rank: 10/25 (Transplantation). Contribution: A,B,C,D

4. **Assy N**, Minuk GY. A comparison between previous and present histologic assessments of chronic hepatitis C viral infection in humans. World J Gastroenterology 1999; 5:107-111.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

Since last promotion

1. Shalata A, Mahroom M, Milewicz DM, Limin G, Kassum F, Badarna K, Tarabeih N, **Assy N**, Fell R, Cohen H, Nashashibi M, Livoff A, Azab M, Habib G, Geiger D, Weissbrod O, Nseir W. Fatal thoracic aortic aneurysm and dissection in a large family with a novel MYLK gene mutation: delineation of the clinical phenotype. Orphanet J Rare Dis. **2018** ;13(1):41.

IF 3.687 Rank: 48/173 (Genetics & Heredity), (D)

2. Meerson A, Najjar A, Saad E, Sbeit W, Barhoum M, **Assy N**. Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients. Noncoding RNA. **2019** ;5(2). pii: E32.

IF 2.03, Rank 7784 (Biochemistry; Genetics; Molecular Biology**)** (A,B,C,D)

3. Saad E, Sbeit W, Barhoum M, Levy G, **Assy N**. Seasonal Patterns of Acute Esophageal Variceal Bleeding in Patients with Liver Cirrhosis. Japanese Journal of Gastroenterology and Hepatology **2020, Jan 22**

IF 1.690, Rank (Gastroenterology & Hepatology), (A,B,C,D)

1. **Case reports**

Until last promotion

1. **Assy N,** Rosenthal E, Hazani A, Etzioni A,Baruch Y. Human parvovirus B19 infection 1associated with idiopathic thrombocytopenic purpura in a child following liver transplantation. J Hepatol 1997:27:934-936.

IF: 9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D

2. Edoute Y, Lachter J, Furman E, and **Assy N**. Severe cholestatic jaundice induced by EBV infection in the elderly. J Gastroenterol Hepatol 1998; 13:821-824.

IF: 2.4, Rank: 33/71(Gastro&hepatol). Contribution: A,B,C,D

3. Miron D, Olshinsky A, **Assy N**, Zuker M, Efrat M, Hussein O. Plasmodium and Borrelia coinfection. J Travel Med 2004; 11:115-116.

IF:1.47, Rank: ? (Infection disease). Contribution: D

**4. Assy N,** Khair G, Sorina Schlesinger, and Osamah Hussein.Severe cholestatic jaundice in the elderly induced by low dose amiodarone. Dig Dis Sci 2004, 49: 450.

IF: 2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

5. **Assy N**, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. World J Gastroenterology 2005; 11:6407-6408.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

6. **Assy N**, Gefen H, Schlesinger S, and Hussein O. The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure Dig Dis Sci. 2007 Apr 5

IF: 2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

7. **Assy N**, Gefen H, Schlesinger S, and Karim W. Reactivation versus primary CMV infection after splenectomy in immunocompetent patient. Dig Dis Sci 2007; 2007 Apr 12.

IF: 2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

8. Benyashvili Z, Djibre A, **Assy N**. Fulminant Kliebsella pneumoniae pneumonia in immunocompromised patient. Clinical Medicine 2008;1: 81-82

IF:1.04, Rank: ? (Gastro&hepatol ). Contribution: A,B,C,D (viewed at libertas academia 1298 times)

9. Nassar F, Nasser M and **Assy N,** Epstein-Barr virus-associated fulminant hepatic failure and autoimmune hemolytic anemia. Gastrohep.com 19 December 2008

10. Samuel N,Ezri Y, Farah R, Vacksman I, Hussein A, Rubinshtein O, **Assy N**. Acute Aflatoxicosis Resulting in Fulminant Hepatic Failure and Rhabdomyolysis. Gastroenterology Research 2009, 2: 48-50

11. Nassar F, Vaisbein E, and **Assy N**. Autoimmune hepatitis - SLE overlap syndrome. Gastrohep.com 30 January 2009

12. G Murad, R Shaheen, R Farah, and **N Assy**, Severe acute cholestatic hepatitis with encephalitis induced by Epstein-Barr virus infection. Gastrohep.com. 22 April 2009

13. Djibre A, Zohar S and **Assy N**, Acute fatty liver of pregnancy. Gastrohep.com 30 March 2010

14. Djibre A, Szvalb S and **Assy N**, D-penicillamine-induced skin elastosis perforans serpiginosa. Gastrohep.com 19 April 2010

Since last promotion

1. A Djibre, N Assy: Recurrent postpartum autoimmune hepatitis Gastrohep.com 11 June 2013

2. W Sbeit, **N Assy**, A Kadah, M Farraj, M Barhoum, M Musa, M Shiller Foley Catheter Gastric Tube Feeding Migration as a Cause of Acute Pancreatitis. Journal of Pancreas. **2017**; 18, 170-174

1. **Review Papers**

Until last promotion

1. Minuk GY and **Assy N.** The consequences of hepatitis C viral infections. Can J Gastroenterology 1995; 9:373-376.

IF: 1.55, Rank: 49/71 (Gastro&hepatol ). Contribution: A,B,C,D

2. **Assy N**, and Minuk GY. Liver regeneration: methods for monitoring and their applications. J Hepatol 1997:26:945-952.

IF: 9.33, Rank: 3/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

3. **Assy N**, and Minuk GY. Liver Disease in pregnancy. J Am Coll Surg 1997; 183:643-653.

IF: 4.2, Rank: 7/40 (Surgery). Contribution: A,B,C,D

4. **Assy N**, Jacob G, Spira G, and Edout Y: Diagnostic approach to patients with cholestatic jaundice. World J Gastroenterology (WJG) 1999; 5:252-262. (Invited review**).**

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

5. Cohen AJ, **Assy N**, Moser M, and Minuk GY. Viral hepatitis and the surgeon. HPB

2005; 7:56-64.

IF:1.285, Rank: 54/71 (Gastro&hepatol. Contribution: A,B,C,D

6. **Assy** **N**, Assy NN, Samuel N, Lerman A, Nseir W. Approach to solid liver masses in the cirrhotic patient. Gastroenterology research. 2009,2: 259-267

IF: 0.5, Rank: ? (Gastro&hepatol ). Contribution: A,B,C,D

7. **Assy N**, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol. 2009 ;15:1809-15.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

8. **Assy N**, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol. 2009; 15:3217-27

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

9. Nseir W, Nassar F, **Assy N.** Soft drinks consumption and nonalcoholic fatty liver disease. World journal Gastroenterol, 2009 Jul 14;15 :3217-27

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D (cited in Wikipedia)

10. Nseir W, Shalata A, Marmor A, and **Assy N.** Mechanisms Linking Non-Alcoholic Fatty Liver Disease with Coronary Artery Disease. Dig Dis SCI 2011; 56:3439-49.

IF:2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

11. **Assy N.** [Nutritional recommendations for patients with non-alcoholic fatty liver diseases.](http://www.ncbi.nlm.nih.gov/pubmed/21876629) World J Gastroenterol. 2011; 17:3375-6

Since promotion

1. Nseir W, Hellou E, **Assy N.** Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. **2014**; 20:9338-44.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology), (A,B,C,D)

2. Elias S, Wisam S, Luai A, Massad B, **Nimer A**. Lipotoxicity in Obesity: Benefit of Olive Oil. Adv Exp Med Biol. **2017**;960:607-617.

IF 2.126 Rank: 86/136 (Medicine, Research & Experimental), (A,B,C,D)

1. **Other Publications** (i.e., Letters to the Editor)

Until last promotion

1. Edoute Y, Malberger E, Tibon-Fisher O, **Assy N**. Non-imaging-guided fine needle aspiration of liver lesions: Invited Commentary WJG 1999; 5:98-102.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

2. **Assy N**, Schlesinger S, Hussein O. Acute hepatitis with extremely high ferritin levels and Still's disease. J Hepatol. 2001; 35:830-831.

IF: 9.33, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

3. **Assy N**, Hussein. Peg interferon and lamivudine for hepatitis B O. New Engl J Med. 2004; 30; 351(27):2879;

IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D

4. **Assy N**, Schlesinger S, and Hussein O. Elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD). Gut 2005;54(5):729

IF: 10.6, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

5. **Assy N**, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. World J Gastroenterology 2005; 11:6402-6402

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

6. **Assy N**, Schlesinger S, Hussein O. Beta-blockers to prevent gastro esophageal varices in cirrhosis. N Engl J Med 2006; 23; 353:1318.

IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D

7. [**Assy N**, Embon O.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17380576&query_hl=12&itool=pubmed_docsum) Peginterferon and ribavirin for hepatitis C. N Engl J Med 2007: 22;356:1269

IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D

8. **Assy N**, Beniashvili Z, Nseir W, and Embon Oscaar. Day-case liver biopsy: a prospective study of 300 cases. Am J Gastroenterology: 2007; 2007; 102:2611-2

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

9. **Assy N**, Adams P, and Ghent CN. A randomized controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut 2007: 56:304-312.

IF: 10.6, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

10. **Assy N**, Nseir W. Letter to the Editor: Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2010; 52:951-954

IF: 9.33, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

11. **Assy N**, Khamayse I. [Sub clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: A randomized controlled study Journal of Hepatology JHEPAT-D-10-00373R3.](http://www.ncbi.nlm.nih.gov/pubmed/21145929) J Hepatol. 2010 Dec

IF: 9.33, Rank: 3/71(Gastro&hepatol). Contribution: A,B,C,D

12. Zelberg-Sagi S, Ratziu V, Oren R. Nutritional and physical activity in NAFLD: An overview of the epidemiological evidence. WJG 2011, (17: 1-0000). Series Editor

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D;

13. **Assy N.** Nutritional recommendation of patients with Nonalcoholic fatty liver diseases (NAFLD). World J Gastroenterol 2011 17:3375-6. Invited Editorial to WJG 2010 as an expert in the field (Highlights 2011):

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D,

Since promotion

1. **Assy N**, Barhoum M. Sofosbuvir and Velpatasvir for Patients with HCV Infection [Letter]. N Engl J Med. 2016;374:1687

IF 70.670 Rank: 1/160 (Medicine, General & Internal) (A,B,C,D)

2. Sbeit W, **Assy N**, Farraj M, Kadah A, Shiller M. Comment on ACG and CAG Clinical Guidelines for Management of Dyspesia. Am J Gastroenterol. 2018; 113:623-624.

IF 10.241 Rank: 7/84 (Gastroenterology & Hepatology), (C,D)

**3. Assy N**, Saad E, Basheer M, Assy Najib and Sbeit W. New Predictor of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. Clin Gastroenterol Int. 2021; 3(1): 1017.

4. Basheer M, Saad E and **Assy N**. Low (HDL) lipoprotein levels is strongly correlated with the severity of Covid -19 pneumonia. Japanese J Gstro Hepato. 2021; V5(12): 1-2

5. Basheer M, Saad E and **Assy N**. Methylprednisolone decrease in hospital mortality in patients with COVID-19 pneumonia. Japanese J Gstro Hepato. 2021; V5(12): 1-1

1. **Book Chapters**

Until last promotion

1. **Assy N**, Nassar F and Grosovski M. Monounsaturated Fat Enriched with Olive Oil in Non-alcoholic Fatty Liver Disease. In: Victor R. Preedy and Ronald Ross Watson, editors, **Olives and Olive Oil in Health and Disease Prevention. Oxford:** Academic Press, 2010, pp. 1151-1156. ISBN: 978-0-12-374420-3 Academic Press. © 2010 Copyright Elsevier Inc

2. Nseir W, and **Assy N.** **Mechanisms Linking Non-Alcoholic Fatty Liver Disease with Coronary Artery Disease. "Coronary Angiography** / Book 3", ISBN 979-953-307-236-3. Full Chapter Submission: 31 March, 2011. InTech - Open Access Publisher. Email: [zgela@intechweb.org](mailto:zgela@intechweb.org). Web: <http://www.intechweb.org/>

Since promotion

1. **N Assy,** F Adawi. W Nseir**. Fructose synthesis function and health implications.** Nutrition and diet research progress. Food Science and Tehnology . 2012 3rd Quarter page 101-106 chapter 5; ISBN 978-1-62081-126-9

2. Elias S., Masad B., **Nimer A.** (2017) **Serum Biomarkers for Evaluating Portal Hypertension.** In: Patel V., Preedy V. (eds) Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht: 153-167

3. Elias S., Wisam S., Luai A., Massad B., **Nimer A**. **Lipotoxicity in Obesity: Benefit of Olive Oil**. In: Engin A., Engin A. (eds) Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology**. Springer, Cham** 2017; 960: 607-617

4. Azulay EE, **Assy N**, Cohen I (November 2018) **Interleukin-1.** In:eLS Immunology. John Wiley &Sons, Ltd: Chischester. DOI:10.1002/9780470015902.a0028193

1. **Books (edited or authored)**

N/A

1. **Publications with No\_IF**

Until promotion

1. **Assy N**. Consequence of Chronic HCV infection. Maccabi Health Service Letters. 1997

2. **Assy N**, Assy N, Samuel N, Lerman A, Nseir W. Approach to solid liver mass in the cirrhotic patient. **Gastroenterology Research**; vol2, N5, OCT 2009

3. Samuel N, Ezri Y, Farah R, Vacksman I, Hussein A, Rubinstein O, **Assy N.** Acute aflatoxicosis resulting in fulminant hepatic failure and rhabdomyolysis. **Gastroenterology Research** VOL2, N 1, FEB 2009

4. Soda Drinks Cause Liver Damage. Sweetened drinks may cause long-term liver damage, advises Israeli physician. Switching to water is the best preventive measure. by Karin Kloosterman. [Israel21c](http://www.israel21c.org/)**.** Published: 09/08/09. http://israel21c.org/health/ israeli-study-soda-and-fruit-juice-drinks-cause-liver-damage

5. **Assy N**: Pharmacological treatment in NAFLD. Led by Oren R; Medical Media, fatty liver 2009

6. Kayal M, Dabus S, **Assy N**. Changes in Kidney Function (GFR) after Furosemide administration in Patients with compensated cirrhosis. The Medical 2009

7. Dabush S, Djibree A, Nseir W, **Assy N**. Pharmacologic treatment of fatty liver.

The Medical 2010

8. **Assy N**, Abu Mouch S. Vitamin D could help fight hepatitis C. Vitamin D may also be key to curing hepatitis. But Israelis, especially the ultra-Orthodox, are woefully deficient. Haaretz Daily 14.01.2010

Papers in press since last promotion

1. Saad E, Barhoum M, Asly M, and **Assy N.** Complete blood count (CBC) parameters as a predictor of the severity of chronic obstructive pulmonary disease (COPD) exacerbation **2020**

2. Dalia David Niv, Lihi Grinberg, Soliman khatib, Jacob Vaya, **Assy Nimer**, David Karasik. Intestinal inflammation and NAFLD induced by western diet in the zebrafish model **2020**

3. Jeremy J Lim, Anna C Nilson, Michael Silverman, **Nimer Assy**, et al. a phase 2 double-blind placebo controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir inpatients hospitalized with severe influenza A infection. Target Journal: Lancet Respiratory Medicine **2020**

4. [D. Hanfelt-Goade](https://www.atsjournals.org/author/Hanfelt-Goade%2C+D), [N. Maimon](https://www.atsjournals.org/author/Maimon%2C+N), [A. Nimer](https://www.atsjournals.org/author/Nimer%2C+A)[4](https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A4457#aff4), [F. Riviere](https://www.atsjournals.org/author/Riviere%2C+F), [E. Catherinot](https://www.atsjournals.org/author/Catherinot%2C+E), [M. Ison](https://www.atsjournals.org/author/Ison%2C+M), [S.H. Jeong](https://www.atsjournals.org/author/Jeong%2C+SH), [E. Walsh](https://www.atsjournals.org/author/Walsh%2C+E), [A. Gafter-Gvili](https://www.atsjournals.org/author/Gafter-Gvili%2C+A), [S.R. Nama](https://www.atsjournals.org/author/Nama%2C+SR), [P. Napora](https://www.atsjournals.org/author/Napora%2C+P) et all . **A** phase 2b, randomized, double blind, placebo controlled trial of presatovir (GS-5806), a novel oral respiratory synctial virus (rsv) fusion inhibitor, for the treatment of RSV in hospitalized adults. American Journal of Respiratory and Critical Care Medicine 2018;197:A4457

**13**. **Patents** (Year, title, status of patent)

2009, Therapy of NAFLD utilizing Inula Viscosa Extract; Grosovski M, Maoz M, **Assy N**.Application Number 199847

**14. Academic Profile**

(התייחסות לתחומי מחקר בלבד ולתרומת המועמד בתחום מחקר. חדשנות רפואית או חדשנות בחינוך רפואי יש לציין במסמכי ההערכה העצמית הנפרדים)

**Main Research Interests and Achievements**

I am the head of the clinical research unit within Internal Medicine Ward A of the Galil Medical Center. This unit has participated in about 60 studies in a variety of internal medicine subjects over the past eight years.

Teaching achievements:

* Teaching Student fourth- and fifth-year medical students a course on liver diseases
* Teaching for clerkship in internal medicine
* Supervised two MD, one PHD and two Master students’ theses
* Teaching residents in internal medicine
* Director of Bioenergetics course at Bar Ilan University

Services achievement:

* Founder of liver clinic in Ziv Medical Center
* Acquired a FIBROSCAN apparatus (70,000 euro) for the liver unit

Other Achievements:

Book chapter on soft drink and fatty liver disease

Two registered patents

Over five invited international talks on liver disease

Three letters in the New England Journal of Medicine

Contributing editor in WJG 2010-2013 and reviewer in many top journals

**Most Research Significant Past Achievements**

Citations: 5783; h-index: 33; i10-index: 58

More than 20 papers in the top five hepatology journals including the Journal of Hepatology (10), Gut (3), Hepatology (2), American Journal of Gastroenterology (5 ), and The New England Journal of Medicine (5 letters).

The most important studies with significant clinical implications are:

1. Soft drinks are linked with fatty liver disease (J Hepatol 2009)
2. Association between cardiovascular disease and fatty liver disease (Radiology 2010)
3. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients (World J Gastroenterol, 2011)
4. IGF-1 generation reflects synthetic liver dysfunction in patients with cirrhosis (J Hepatol 1997)
5. Sedation with propofil in patients with cirrhosis (J Hepatol 2010, Gastrointestinal Endoscopy 1999)
6. VEGF role in liver regeneration (J Hepatol, 1999)
7. New molecular (PCNA) marker to document extent of liver regeneration (J Lab Clin Med 1998)

**Future Research Goals**

* Further promote my research lab at the Galil Medical Center, supervising MSc and PhD students.
* Continue clinical medical research with pharmaceutical companies.
* Continue teaching in the Faculty of Medicine: clerkships, bioenergetics, liver disease, liver transplantation
* Maintain the department’s position as the most prolific and productive department of internal medicine at Bar Ilan University.